Healthy longevity of women: what can a gynecologist do?
https://doi.org/10.14341/probl13644
Abstract
A woman spends more than a third of her life in a state of deficiency of female sex hormones. According to WHO, in most countries of the world the life expectancy of women after 50 years fluctuates between 27 and 32 years. Every year the number of women entering the menopause period increases. In 1990, 467 million were in the postmenopause period, by 2030 the number will reach 1.2 billion. Menopause, not being a disease itself, leads to a violation of the endocrine balance in the body, causing not only «classic» problems in life (vasomotor symptoms, psychological health disorders, urogenital disorders, osteoporosis, cardiovascular diseases), but also changes the appearance of women — the dermatological status of the patient is worse than the age group. The article presents modern data on rational MHT. Particular attention is paid to the issues of efficacy, tolerability and safety of combined MHT containing estrogen and gestagen, based on the results of current studies and in accordance with the position of national and international clinical guidelines. A clinical case is used to demonstrate the tactics of managing a woman in menopause.
About the Authors
E. N. AndreevaRussian Federation
Elena N. Andreeva, MD, PhD, professor
Moscow
E. V. Sheremetyeva
Russian Federation
Ekaterina V. Sheremetyeva, MD, PhD
11 Dm. Ulyanova street, 117036 Moscow
O. R. Grigoryan
Russian Federation
Olga R. Grigoryan, MD, PhD, professor
Moscow
References
1. АAndreeva EN, Sheremetyeva EV, Grigoryan OR, Altaeva AA. The effect of menopausal hormone therapy on the dermatological status of postmenopausal women or an interdisciplinary approach in anti-age protocols for the integrated management of postmenopausal women. Russian Journal of Human Reproduction. 2023;29(2):70-80. (In Russ.). doi: https://doi.org/10.17116/repro20232902170
2. World report on ageing and health. WHO Library Cataloguing-in-Publication Data 2016
3. Tapilskaya N.I., Bespalova O.N., Kogan I.Yu. Justification for the choice of menopausal hormone therapy when there is a need to change treatment in the context of a personalized approach. // Obstetrics and Gynecology. — 2022; — No. 10. — P. 178-184. doi: https://dx.doi.org/10.18565/aig.2022.10.178-184
4. Ulumbekova G.E., Khudova I.Yu. Assessment of the demographic, social and economic effect of menopausal hormone therapy. ORGZDRAV: news, opinions, training. // Bulletin of the Higher School of Health. — 2020. — Vol. 6. — No. 4. — P. 23-53. doi: https://dx.doi.org/10.24411/2411-8621-2020-14002.
5. Clinical guidelines (project) «Menopause and climacteric condition», Moscow, 2024
6. Algorithms for the use of menopausal hormone therapy in women during the peri- and postmenopause. Joint position of experts of the Russian Society of Obstetricians and Gynecologists, Russian Academy of Medical Sciences, the Academy of Gynecology and Public Health, and the Russian Academy of Organ and Organ Society / edited by V.N. Serov, S.V. Yureneva. // Obstetrics and Gynecology. — 2021. — No. 3. — P. 210-221. doi: https://dx.doi.org/10.18565/aig.2021.3.210-221
7. Yureneva S.V., Dubrovina A.V. Advantages of early/timely start of menopausal hormone therapy from the standpoint of the theory of euestrogens. // Russian Bulletin of Obstetrician-Gynecologist. — 2018. — Vol. 18. — No. 5. — P. 49-55.
8. NICE guideline Menopause: diagnosis and management (NG23, published Nov 2015). Available at: nice.org.uk/guidance/NG23. Accessed 20 Jan 2021
9. Rules for conducting bioequivalence studies of medicinal products within the framework of the Eurasian Economic Union (Decision of the Council of the Eurasian Economic Commission of November 3, 2016 No. 85)
10. “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi: https://doi.org/10.1097/GME.0000000000002200
11. Cameron CR, Cohen S, Sewell K, Lee M. The Art of Hormone Replacement Therapy (HRT) in Menopause Management. J Pharm Pract. 2024;37(3):736-740. doi: https://doi.org/10.1177/08971900231167925
12. Yang JL, Hodara E, Sriprasert I, Shoupe D, Stanczyk FZ. Estrogen deficiency in the menopause and the role of hormone therapy: integrating the findings of basic science research with clinical trials. Menopause. 2024;31(10):926-939. doi: https://doi.org/10.1097/GME.0000000000002407
Review
For citations:
Andreeva E.N., Sheremetyeva E.V., Grigoryan O.R. Healthy longevity of women: what can a gynecologist do? Problems of Endocrinology. 2025;71(4):95-102. (In Russ.) https://doi.org/10.14341/probl13644

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).